Key facts
- This page summarizes Jami Rubin's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2024, 16:06.
Jami Rubin - 10 Jun 2024 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)
- Reporting relationship
- Director
- Issuer ticker
- RLAY
- Reported as of
- 10 Jun 2024
- Net transaction value
- +$212,900
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2024, 16:06:28 UTC
- Prior SEC filing
- 05 Jun 2024
- Next SEC filing
- 20 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Adams, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jami Rubin filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 12 Jun 2024.
Change
- Previous filing in this sequence was filed on 05 Jun 2024.
- Current net transaction value: +$212,900.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RLAY
transaction
Common Stock
Options Exercise
- Transaction value
- $212,900
- Shares
- +42,242
- Change %
- +169%
- Price
- $5.04
- Shares after
- 67,242
- Date
- 10 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RLAY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -42,242
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 10 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,242
- Exercise price
- $5.04
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
Footnote F2
This stock option vested in sixteen (16) equal quarterly installments following the vesting commencement date of October 10, 2019, subject to the reporting person's continued service relationship through each vesting date.